Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Dec 1;29(12):2396-2398.
doi: 10.1093/annonc/mdy453.

Impact of antibiotic use on survival in patients with advanced cancers treated on immune checkpoint inhibitor phase I clinical trials

S Sen  1 , R Carmagnani Pestana  2 , K Hess  3 , G M Viola  4 , V Subbiah  5
Affiliations

Impact of antibiotic use on survival in patients with advanced cancers treated on immune checkpoint inhibitor phase I clinical trials

S Sen et al. Ann Oncol. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
PFS and OS in patients treated with immune checkpoint inhibitors (ICI) in phase I clinical trials by antibiotic (ATB) use. There was no difference in PFS in patients that used ATB compared with those who did not, regardless of timing of ATB use (A, use during ICI use; B, use within 30 days of ICI; C, use 30–60 days before ICI). OS was significantly worse in patients that used ATB within 30 days of ICI use (E); no difference in OS for patients that used ATB during ICI use (D) or 30–60 days before ICI (F).
See this image and copyright information in PMC

References

    1. Derosa L, Hellmann MD, Spaziano M. et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol 2018; 29(6): 1437–1444. - PMC - PubMed
    1. Gilbert JA, Blaser MJ, Caporaso JG. et al. Current understanding of the human microbiome. Nat Med 2018; 24(4): 392. - PMC - PubMed
    1. Vétizou M, Pitt JM, Daillère R. et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 2015; 350(6264): 1079. - PMC - PubMed
    1. Modi SR, Collins JJ, Relman DA.. Antibiotics and the gut microbiota. J Clin Invest 2014; 124(10): 4212–4218. - PMC - PubMed
    1. Routy B, Le Chatelier E, Derosa L. et al. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors. Science 2018; 359(6371): 91. - PubMed

Publication types

MeSH terms